Predictive Oncology Inc. (POAI): Price and Financial Metrics

Predictive Oncology Inc. (POAI): $0.34

-0.04 (-9.58%)

POWR Rating

Component Grades













Add POAI to Watchlist
Sign Up

Industry: Biotech



in industry


  • POAI scores best on the Growth dimension, with a Growth rank ahead of 79.07% of US stocks.
  • POAI's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • POAI ranks lowest in Value; there it ranks in the 2nd percentile.

POAI Stock Summary

  • POAI's price/sales ratio is 54.56; that's higher than the P/S ratio of 96.33% of US stocks.
  • With a year-over-year growth in debt of -86.41%, Predictive Oncology Inc's debt growth rate surpasses only 2.53% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for POAI comes in at -69.65% -- higher than that of only 6.05% of stocks in our set.
  • Stocks that are quantitatively similar to POAI, based on their financial statements, market capitalization, and price volatility, are LOCO, AEL, UAMY, TDW, and MXC.
  • POAI's SEC filings can be seen here. And to visit Predictive Oncology Inc's official web site, go to

POAI Valuation Summary

  • POAI's price/sales ratio is 49.8; this is 1210.53% higher than that of the median Healthcare stock.
  • Over the past 138 months, POAI's price/sales ratio has gone down 212.7.
  • Over the past 138 months, POAI's EV/EBIT ratio has gone up 0.4.

Below are key valuation metrics over time for POAI.

Stock Date P/S P/B P/E EV/EBIT
POAI 2021-08-31 49.8 1.3 -2.8 -1.1
POAI 2021-08-30 49.8 1.3 -2.8 -1.1
POAI 2021-08-27 50.7 1.3 -2.9 -1.1
POAI 2021-08-26 51.7 1.4 -2.9 -1.2
POAI 2021-08-25 51.2 1.4 -2.9 -1.2
POAI 2021-08-24 51.7 1.4 -2.9 -1.2

POAI Growth Metrics

    The 4 year revenue growth rate now stands at 141.88%.
  • The 5 year cash and equivalents growth rate now stands at 20.52%.
  • The year over year net cashflow from operations growth rate now stands at -30.55%.
POAI's revenue has moved down $173,680 over the prior 33 months.

The table below shows POAI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 1.237975 -10.76877 -23.37064
2021-06-30 1.405069 -11.06363 -24.79463
2021-03-31 1.237646 -12.60684 -25.79808
2020-12-31 1.252272 -12.25773 -26.43868
2020-09-30 1.305961 -12.74943 -28.66662
2020-06-30 1.3479 -11.40804 -25.93892

POAI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • POAI has a Quality Grade of D, ranking ahead of 8.37% of graded US stocks.
  • POAI's asset turnover comes in at 0.042 -- ranking 162nd of 186 Medical Equipment stocks.
  • INO, EYES, and PETV are the stocks whose asset turnover ratios are most correlated with POAI.

The table below shows POAI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.042 0.637 -7.254
2021-03-31 0.047 0.635 -18.054
2020-12-31 0.055 0.643 58.433
2020-09-30 0.052 0.629 16.113
2020-06-30 0.050 0.616 9.041
2020-03-31 0.052 0.621 9.870

POAI Price Target

For more insight on analysts targets of POAI, see our POAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 1.5 (Moderate Buy)

POAI Stock Price Chart Interactive Chart >

Price chart for POAI

POAI Price/Volume Stats

Current price $0.34 52-week high $1.64
Prev. close $0.38 52-week low $0.25
Day low $0.34 Volume 3,229,700
Day high $0.40 Avg. volume 783,604
50-day MA $0.78 Dividend yield N/A
200-day MA $0.96 Market Cap 22.73M

Predictive Oncology Inc. (POAI) Company Bio

Predictive Oncology Inc. operates as a biotechnology company. The Company focuses focuses on applying data and artificial intelligence to personalized medicine and drug discovery. Predictive Oncology serves customers worldwide.

POAI Latest News Stream

Event/Time News Detail
Loading, please wait...

POAI Latest Social Stream

Loading social stream, please wait...

View Full POAI Social Stream

Latest POAI News From Around the Web

Below are the latest news stories about Predictive Oncology Inc that investors may wish to consider to help them evaluate POAI as an investment opportunity.

A Quick Glance At Predictive Oncology Inc. (NASDAQ: POAI) Stock: It Is up 1.37% From Its 52-Week Low; YTD, It Is Down -23.07 Percent

During the last session, Predictive Oncology Inc. (NASDAQ:POAI)s traded shares were 0.27 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stocks price was $0.73, reflecting an intraday loss of -2.36% or -$0.02. The 52-week high for the POAI share is $2.20, that puts it down A Quick Glance At Predictive Oncology Inc. (NASDAQ: POAI) Stock: It Is up 1.37% From Its 52-Week Low; YTD, It Is Down -23.07 Percent Read More »

Marketing Sentinel | February 19, 2022

Predictive Oncology set to market AI drug discovery platform

MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI ) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its strategy for 2022. The Company plans to leverage its existing pharma relationships to market PeDAL™ in a move that will take the proprietary platform out of the research lab into the pipelines of oncology drug discovery companies. POAI recently completed its Discovery 21 evaluation, the proof of concept for PeDAL. CoRE™, POAI''s Artificial Intelligence program, together with tumor profile data, human tumor samples and active machine learning, power PeDAL to determine the most effective drug treatmen...

Benzinga | January 27, 2022

Predictive Oncology AI program identifies potential cancer drug uses

Predictive Oncology (POAI) said its Helomics subsidiary''s evaluation showed that its Artificial Intelligence (AI) program CoRE (Computational Research Engine), combined with tumor…

Seeking Alpha | January 13, 2022

POAI Reports Strong Results From Its AI Cancer Drug Evaluation

MINNEAPOLIS, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE™ (Computational Research Engine), combined with their tumor profile data and matched ovarian cancer samples, could identify potential new chemotherapy drug uses. These drugs are not currently approved for ovarian canc

Yahoo | January 13, 2022

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

Penny stocks under $3 are full of potential and potential pitfalls.

Alex Sirois on InvestorPlace | December 31, 2021

Read More 'POAI' Stories Here

POAI Price Returns

1-mo -51.63%
3-mo -52.58%
6-mo -68.22%
1-year -67.62%
3-year -93.87%
5-year -98.08%
YTD -64.28%
2021 29.97%
2020 -71.94%
2019 -57.90%
2018 -38.61%
2017 -63.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9581 seconds.